NCT00676026View on ClinicalTrials.gov

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Healthy
Interventions
DRUG

Fluoxetine

Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.

DRUG

Zolpidem

Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.

DRUG

Progesterone

Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.

Trial Locations (1)

06511

Yale University School of Medicine; Yale Program for Women's Reproductive Behavioral Health, New Haven

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT00676026 - Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women | Biotech Hunter | Biotech Hunter